See more : AVEO Pharmaceuticals, Inc. (AVEO) Income Statement Analysis – Financial Results
Complete financial analysis of Meiji Holdings Co., Ltd. (MEJHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Meiji Holdings Co., Ltd., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- Orpea SA (ORP.PA) Income Statement Analysis – Financial Results
- Origo hf. (ORIGO.IC) Income Statement Analysis – Financial Results
- Aica Kogyo Company, Limited (4206.T) Income Statement Analysis – Financial Results
- Deutsche Post AG (DPW.SW) Income Statement Analysis – Financial Results
- Whitbread plc (WTBDY) Income Statement Analysis – Financial Results
Meiji Holdings Co., Ltd. (MEJHF)
About Meiji Holdings Co., Ltd.
Meiji Holdings Co., Ltd., through its subsidiaries, manufactures and sells dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, cheese, drinking milk, beverages, butter and margarine, cream, ice cream, ready meals, chocolates, gummy products, chewing gums, sports nutrition products, infant formula, liquid diet, beauty supplements, OTC medicines, feed stuffs, corn sweeteners, and sugar, as well as transportation and distribution services. The company also offers drugs for infectious diseases and central nervous system disorders, as well as generic drugs; agricultural and livestock chemicals; human and animal vaccines, and blood plasma products; and veterinary drugs for livestock and fisheries comprising antimicrobial injection, disinfectants, oral administration, insecticides, anthelmintic, antipyretic, analgesic, anti-inflammatory, hemostatic, and breeding agents. In addition, it provides insecticides, metabolites, feed additives, and mixed feed; and companion animals, including anesthetics and painkillers, anti-parasitic and gastrointestinal drugs, anti-bacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,105.49B | 7.99B | 8.32B | 10.79B | 11.60B | 11.33B | 11.67B | 11.15B | 10.89B | 1,161.15B | 1,148.08B | 1,126.52B | 1,109.28B | 1,111.00B | 1,106.66B | 711.39B | 706.99B | 702.75B | 710.91B |
| Cost of Revenue | 778.15B | 5.69B | 5.67B | 6.72B | 7.32B | 7.21B | 7.39B | 7.01B | 6.92B | 757.77B | 754.01B | 743.84B | 738.50B | 732.93B | 734.68B | 522.66B | 516.33B | 502.64B | 515.71B |
| Gross Profit | 327.35B | 2.31B | 2.66B | 4.07B | 4.28B | 4.12B | 4.28B | 4.14B | 3.96B | 403.39B | 394.06B | 382.69B | 370.78B | 378.07B | 371.98B | 188.74B | 190.66B | 200.12B | 195.20B |
| Gross Profit Ratio | 29.61% | 28.88% | 31.91% | 37.73% | 36.92% | 36.40% | 36.66% | 37.13% | 36.41% | 34.74% | 34.32% | 33.97% | 33.42% | 34.03% | 33.61% | 26.53% | 26.97% | 28.48% | 27.46% |
| Research & Development | 34.88B | 233.25M | 274.72M | 284.20M | 291.29M | 263.65M | 249.24M | 234.78M | 242.96M | 26.11B | 26.07B | 26.20B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 176.69B | -37.52B | -37.51B | -141.74B | -147.79B | -146.48B | -153.68B | -162.43B | -162.34B | 195.66B | 194.23B | 190.41B | 0.00 | 0.00 | 0.00 | 174.70B | 174.40B | 176.52B | 175.21B |
| Selling & Marketing | 40.99B | 39.03B | 39.13B | 144.55B | 150.83B | 149.43B | 156.80B | 165.52B | 165.35B | 154.38B | 160.61B | 161.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 217.68B | 1.51B | 1.62B | 2.82B | 3.03B | 2.95B | 3.12B | 3.09B | 3.01B | 350.04B | 354.84B | 351.56B | 0.00 | 0.00 | 0.00 | 174.70B | 174.40B | 176.52B | 175.21B |
| Other Expenses | 0.00 | -1.27B | -1.99B | -17.07M | -17.67M | -22.07M | -18.27M | -18.50M | -16.83M | 1.24B | 1.53B | 2.68B | 2.64B | 3.59B | 2.73B | 25.00M | 168.00M | 0.00 | 0.00 |
| Operating Expenses | 243.02B | 1.74B | 1.89B | 3.12B | 3.34B | 3.24B | 3.39B | 3.35B | 3.27B | 351.84B | 357.57B | 356.83B | 350.58B | 348.11B | 343.19B | 174.70B | 174.40B | 176.52B | 175.21B |
| Cost & Expenses | 1,021.17B | 7.43B | 7.56B | 9.84B | 10.66B | 10.44B | 10.78B | 10.36B | 10.20B | 1,109.61B | 1,111.58B | 1,100.66B | 1,089.08B | 1,081.04B | 1,077.87B | 697.36B | 690.73B | 679.15B | 690.92B |
| Interest Income | 488.00M | 2.94M | 2.14M | 2.62M | 2.12M | 1.17M | 1.34M | 1.18M | 1.36M | 96.00M | 66.00M | 46.00M | 54.00M | 45.00M | 63.00M | 481.00M | 480.00M | 557.00M | 639.00M |
| Interest Expense | 367.00M | 3.48M | 4.11M | 5.63M | 6.64M | 7.03M | 7.10M | 7.13M | 8.75M | 1.12B | 1.29B | 1.55B | 1.98B | 2.21B | 2.57B | 1.18B | 864.00M | 989.00M | 1.06B |
| Depreciation & Amortization | 55.33B | 53.59B | 50.12B | 48.43B | 46.23B | 44.67B | 48.15B | 47.48B | 43.85B | 42.52B | 41.11B | 40.95B | 41.12B | 41.68B | 39.49B | 20.23B | 22.08B | 19.68B | 20.30B |
| EBITDA | 143.20B | 129.03B | 143.04B | 154.49B | 144.70B | 143.06B | 142.83B | 135.87B | 121.64B | 94.06B | 77.61B | 67.71B | 64.98B | 74.34B | 70.38B | 34.87B | 38.76B | 43.95B | 40.49B |
| EBITDA Ratio | 12.95% | 12.15% | 14.12% | 12.87% | 11.80% | 11.40% | 11.51% | 10.94% | 9.94% | 8.44% | 7.10% | 6.36% | 5.86% | 6.69% | 6.36% | 4.90% | 5.53% | 6.25% | 5.76% |
| Operating Income | 84.32B | 567.80M | 763.35M | 950.09M | 941.27M | 888.86M | 890.21M | 793.29M | 692.03M | 51.54B | 36.50B | 25.86B | 20.19B | 32.66B | 30.89B | 14.64B | 17.05B | 24.27B | 20.66B |
| Operating Income Ratio | 7.63% | 7.10% | 9.17% | 8.81% | 8.11% | 7.84% | 7.63% | 7.11% | 6.36% | 4.44% | 3.18% | 2.30% | 1.82% | 2.94% | 2.79% | 2.06% | 2.41% | 3.45% | 2.91% |
| Total Other Income/Expenses | 3.19B | 19.98B | -91.87B | -2.88B | -4.96B | -3.80B | -3.59B | 88.40B | 17.43B | -2.89B | -2.81B | -645.00M | -5.60B | -12.04B | -4.69B | -2.23B | -446.00M | -2.17B | -856.00M |
| Income Before Tax | 87.51B | 718.15M | 1.06B | 933.78M | 905.46M | 854.55M | 856.41M | 800.43M | 847.10M | 48.66B | 33.69B | 25.21B | 14.59B | 17.93B | 24.10B | 11.81B | 15.82B | 21.43B | 19.13B |
| Income Before Tax Ratio | 7.92% | 8.98% | 12.68% | 8.66% | 7.80% | 7.54% | 7.34% | 7.18% | 7.78% | 4.19% | 2.93% | 2.24% | 1.32% | 1.61% | 2.18% | 1.66% | 2.24% | 3.05% | 2.69% |
| Income Tax Expense | 33.79B | 179.99M | 296.30M | 299.57M | 259.29M | 279.85M | 273.78M | 251.20M | 281.21M | 17.19B | 14.69B | 8.37B | 7.54B | 8.34B | 10.58B | 5.84B | 6.55B | 7.70B | 8.98B |
| Net Income | 50.68B | 522.56M | 718.79M | 594.17M | 623.57M | 558.96M | 576.20M | 545.51M | 556.79M | 30.89B | 19.06B | 16.65B | 6.81B | 9.55B | 13.09B | 5.93B | 9.23B | 13.71B | 10.06B |
| Net Income Ratio | 4.58% | 6.54% | 8.64% | 5.51% | 5.37% | 4.93% | 4.94% | 4.89% | 5.11% | 2.66% | 1.66% | 1.48% | 0.61% | 0.86% | 1.18% | 0.83% | 1.30% | 1.95% | 1.41% |
| EPS | 181.64 | 1.86 | 2.49 | 2.05 | 2.15 | 1.93 | 1.98 | 1.85 | 1.89 | 104.89 | 64.70 | 56.49 | 23.10 | 32.41 | 44.43 | 4.51 | 7.02 | 10.43 | 8.47 |
| EPS Diluted | 181.64 | 1.86 | 2.49 | 2.05 | 2.15 | 1.93 | 1.98 | 1.85 | 1.89 | 104.89 | 64.70 | 56.49 | 23.10 | 32.41 | 44.43 | 4.51 | 7.02 | 10.43 | 8.47 |
| Weighted Avg Shares Out | 278.98M | 280.63M | 288.18M | 290.18M | 290.12M | 290.05M | 290.31M | 294.29M | 294.45M | 294.50M | 294.60M | 294.65M | 294.67M | 294.75M | 294.56M | 219.05M | 219.08M | 219.05M | 198.01M |
| Weighted Avg Shares Out (Dil) | 278.98M | 280.63M | 288.18M | 290.18M | 290.12M | 290.05M | 290.31M | 294.29M | 294.45M | 294.50M | 294.60M | 294.65M | 294.67M | 294.75M | 294.56M | 219.05M | 219.08M | 219.05M | 198.01M |
Source: https://incomestatements.info
Category: Stock Reports